Biological therapy for inflammatory bowel disease

Velocity aggressively expands MASH/MASLD capabilities with latest site acquisitions

Retrieved on: 
Wednesday, October 25, 2023
Potsdam Institute for Climate Impact Research, Gastroenterology, FDA, Research, Oregon Health & Science University, United States Department of the Air Force, Obesity, General Social Care Council, Prevalence, Biological therapy for inflammatory bowel disease, Liver disease, Paulinum (University of Leipzig), ChromeOS, CPI, Tufts University School of Medicine, AGAF, Growth, Disease, St George's Hospital, NASH, University, KOL, Internal medicine, Icahn School of Medicine at Mount Sinai, Air force, Brooke Army Medical Center, DURHAM, FACP, FACG, Hepatology, Veteran, Patient, MASH, Dietary supplement, Pharmaceutical industry, Medical device, Nursing, MD, Velocity

DURHAM N.C., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Velocity Clinical Research (“Velocity”), the leading multi-specialty clinical sites business, announced it has acquired Impact Research Institute (Waco, TX) and the clinical trials unit of Liver Institute Northwest (Seattle, WA), aggressively expanding its capabilities in liver disease research, including MASH (metabolic dysfunction-associated steatohepatitis) and MASLD (metabolic dysfunction-associated steatotic liver disease).

Key Points: 
  • Velocity is a major player in this space with 23 sites capable of performing MASH/MASLD studies globally.
  • With the two recent site acquisitions, Velocity adds two internationally renowned researchers and key opinion leaders (KOL) in liver disease research as principal investigators, Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, and Nadege Gunn, MD, CPI, who join Roland Kuchta, MD, in Germany.
  • Dr. Gunn commented, “We are fully prepared to make Velocity the first-choice site network for liver disease clinical trials worldwide.
  • Velocity has over 80 locations globally and access to more than 220 principal investigators and one million patients.

Mining for Miracles Eyes 2022 Completion of $3.385 Million Fundraising Goal to Establish Cellular and Regenerative Medicine Centre (CRMC) at BC Children’s Hospital

Retrieved on: 
Thursday, February 17, 2022
Health, BC Children's Hospital Foundation, Arrhythmia, Hospital, Biological therapy for inflammatory bowel disease, Epilepsy, British Columbia Children's Hospital, Uncertainty, Cancer, Head, Risk, Man, Social media, Mining, Cardiac arrest, GLOBE, Miner, Cell, Division, Dream, Woman, Diabetes, Regenerative medicine, Child, Acquisition, Blood, Arrest, Leg, Research, Diagnosis, Genetics, Industry, Property management, Pharmaceutical industry, Health insurance, Dentistry, Teck, BC, Cardiology

VANCOUVER, British Columbia, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Mining for Miracles, the BC mining industrys long-standing fundraising campaign for BC Childrens Hospital Foundation, launched its 2022 campaign today with Premier John Horgan, in support of BC Childrens Hospitals Cellular and Regenerative Medicine Centre (CRMC), the first of its kind in Western Canada.

Key Points: 
  • VANCOUVER, British Columbia, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Mining for Miracles, the BC mining industrys long-standing fundraising campaign for BC Childrens Hospital Foundation, launched its 2022 campaign today with Premier John Horgan, in support of BC Childrens Hospitals Cellular and Regenerative Medicine Centre (CRMC), the first of its kind in Western Canada.
  • In 2022, Mining for Miracles launches the final leg of their campaign to fulfill their commitment, made in 2020, to establish the CRMC, a $3.385 million initiative.
  • We receive incredible support for the annual Mining for Miracles campaign from the thousands of women and men who work in the mining industry.
  • BC Childrens has the clinical and scientific expertise to be leaders in pediatric cellular and regenerative medicine, but they require infrastructure and equipment to do this.

Bacainn Therapeutics Presents at ECCO ‘21 Results from Phase 1 Study that Shows BT051, an Oral, Locally-Acting Inhibitor of Neutrophil Trafficking and Activity, Is Safe and Well-Tolerated in Healthy Adults

Retrieved on: 
Friday, July 9, 2021
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, Medical specialties, Clinical medicine, Medicine, Autoimmune diseases, Abdominal pain, Colitis, Diarrhea, Ulcerative colitis, Inflammatory bowel disease, Biological therapy for inflammatory bowel disease, the Phase 1 Study, Bacainn Therapeutics, THE PHASE 1 STUDY, BACAINN THERAPEUTICS

People with IBD need additional therapeutic options as their disease progresses, said Chris Stevens, MD, Chief Medical Officer at Bacainn Therapeutics.

Key Points: 
  • People with IBD need additional therapeutic options as their disease progresses, said Chris Stevens, MD, Chief Medical Officer at Bacainn Therapeutics.
  • In this Phase 1 study, single-dose administration of BT051 was generally safe and well-tolerated with minimal systemic exposure, while BT051 stool concentrations were significantly above the predicted efficacy range.
  • Taken together, these data support the continued development of BT051 as a gut-targeted therapy for people with moderate-to-severe ulcerative colitis.
  • Bacainn Therapeutics is developing novel therapies that target the innate immune system to address uncontrolled inflammation in serious gastrointestinal and respiratory diseases.

Heat Biologics Announces Significant Expansion of R&D and Pre-Clinical Capabilities at Corporate Headquarters

Retrieved on: 
Wednesday, June 23, 2021
Life sciences, Health sciences, Natural sciences, Biotechnology, Pharmaceutical industry, Biopharmaceutical, Pharmacy, Heat Biologics, Therapy, Biological therapy for inflammatory bowel disease

The expansion will support the addition of enhanced research and development capabilities including in-house synthesis of antibodies and other drugs/reagents as well as an expanded vivarium for onsite pre-clinical studies.

Key Points: 
  • The expansion will support the addition of enhanced research and development capabilities including in-house synthesis of antibodies and other drugs/reagents as well as an expanded vivarium for onsite pre-clinical studies.
  • Jeff Wolf, Chief Executive Officer of Heat Biologics, stated, We are delighted to announce plans to double the size of the current facilities to support and accelerate activities around our oncology and non-oncology programs.
  • We look forward to leveraging these new facilities as we accelerate our discovery and development efforts.
  • Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system.

Upcoming Oral, Small Molecule Agents Expected to Leapfrog Existing Biologic Treatment and Become Foundational Inflammatory Bowel Disease Therapies

Retrieved on: 
Wednesday, March 24, 2021
Life sciences, Health sciences, Biotechnology, Pharmaceutical industry, Drug discovery, Biopharmaceutical, Pharmacy, Topix, Therapy, Biological therapy for inflammatory bowel disease

This new Special Topix service was created in response to the three oral, small molecule therapies currently in Phase 3 development for the treatment of IBD and the additional three therapies with Phase 2 clinical data.

Key Points: 
  • This new Special Topix service was created in response to the three oral, small molecule therapies currently in Phase 3 development for the treatment of IBD and the additional three therapies with Phase 2 clinical data.
  • The combination of qualitative and quantitative research included in the Special Topix service evaluates, in detail, the current treatment algorithm for pre-advanced systemic therapies, the decision point at which IBD patients are switched to biologics, and key physician reactions to oral, small molecule therapies in development.
  • Fear of side effects and concerns about safety are leading barriers for IBD patients starting biologic therapy.
  • Prospects for oral, small molecule therapies currently in development are also captured in the full report.

Avexegen Therapeutics Receives a $2.94M NIH Grant to Advance Treatment for Inflammatory Bowel Disease

Retrieved on: 
Monday, February 15, 2021
Medical specialties, Clinical medicine, Medicine, Autoimmune diseases, Abdominal pain, Diarrhea, Colitis, Crohn's disease, Ulcerative colitis, Inflammatory bowel disease, Biological therapy for inflammatory bowel disease

IBD affects over 3 million patients in the US and is almost equally manifested as Crohn's Disease and ulcerative colitis.

Key Points: 
  • IBD affects over 3 million patients in the US and is almost equally manifested as Crohn's Disease and ulcerative colitis.
  • "Avexegen will use the NIH funds to develop an orally efficacious, NRG-4-based drug product with localized action in the gut and a superior safety profile,"said Dr. Soumitra Ghosh, the Principal Investigator in the SBIR grant.
  • "We believe that an NRG-4-based drug product, with its compelling pharmacology, has the potential to be a standalone IBD treatment or an important complement to other treatment approaches to significantly improve disease remission and long-term outcomes," added Artin Asadourian, CEO of Avexegen Therapeutics.
  • The content is solely the responsibility of the company and does not necessarily represent the official views of the National Institutes of Health.

Tiziana Life Sciences to Participate in a Fireside Chat at B. Riley Virtual Oncology Investor Conference on 21 January 2021 at 3 pm ET/8 pm GMT

Retrieved on: 
Wednesday, January 20, 2021
Medical specialties, Clinical medicine, Monoclonal antibodies, Medicine, Immunology, Interleukin-6 receptor, Anti-CD3 monoclonal antibody, Foralumab, Antibody, Interleukin 6, Monoclonal antibody therapy, Biological therapy for inflammatory bowel disease

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology.

Key Points: 
  • Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology.
  • In addition to Milciclib, the Company is also developing Foralumab for liver diseases.
  • Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world.
  • The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.

Tiziana Life Sciences to Host Investor Update Call on 2 December 2020 at 4:15 p.m. ET

Retrieved on: 
Tuesday, December 1, 2020
Medical specialties, Clinical medicine, Monoclonal antibodies, Medicine, Immunology, Interleukin-6 receptor, Anti-CD3 monoclonal antibody, Foralumab, Antibody, Interleukin 6, Monoclonal antibody therapy, Biological therapy for inflammatory bowel disease

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology.

Key Points: 
  • Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology.
  • In addition to Milciclib, the Company is also developing Foralumab for liver diseases.
  • Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world.
  • The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.

Applied Molecular Transport Announces Publication of Preclinical Data Demonstrating Potential of Novel Oral IL-10 Biologic Therapeutic (AMT-101) for Inflammatory Diseases in The Journal of Immunology

Retrieved on: 
Tuesday, November 10, 2020
Medical specialties, Branches of biology, Clinical medicine, Immunology, Interleukins, Cytokine, Transcytosis, Autoimmunity, Inflammation, Sjögren syndrome, Biological therapy for inflammatory bowel disease, Interleukin 18

IL-10 is a potent immunomodulatory cytokine with significant therapeutic potential in intestinal inflammatory diseases as well as in those associated with systemic inflammation.

Key Points: 
  • IL-10 is a potent immunomodulatory cytokine with significant therapeutic potential in intestinal inflammatory diseases as well as in those associated with systemic inflammation.
  • However, clinical utilization of IL-10 to treat inflammation and immune-dysregulation has been limited due to side effects associated with systemic administration.
  • Our technology platform is based on native, active vesicular transcytosis mechanisms to rapidly and efficiently traverse intestinal epithelial cells.
  • Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases.

VBL Presents New Data on MOSPD2 Antibodies as Potential Treatment for NASH and Colitis at DDW

Retrieved on: 
Wednesday, May 6, 2020
Medical specialties, Medicine, Clinical medicine, Immunology, Diarrhea, Autoimmune diseases, Monoclonal antibodies, Colitis, Inflammation, Gastrointestinal disease, Biological therapy for inflammatory bowel disease, Crohn's disease

Treatment with anti-MOSPD2 antibodies was shown to decrease inflammation and fibrosis in a NASH model and significantly reduce disease activity in a colitis model.

Key Points: 
  • Treatment with anti-MOSPD2 antibodies was shown to decrease inflammation and fibrosis in a NASH model and significantly reduce disease activity in a colitis model.
  • VBL's ePoster entitled MOSPD2: A novel therapeutic target for the treatment of inflammatory digestive disorders, was presented at the Digestive Disease Week (DDW) 2020 virtual meeting.
  • VBL's data demonstrate that MOSPD2 plays a role in the pathogenesis of NASH and colitis, by inhibiting the accumulation of monocytes in the affected tissue.
  • Targeting of MOSPD2 using specific monoclonal antibodies, such as the proprietary ones developed by VBL, may offer a novel and distinct treatment for chronic immune-inflammatory indications including colitis and NASH.